US2016355884A1PendingUtilityA1

Gene signatures for cancer prognosis

Assignee: MYRIAD GENETICS INCPriority: Jul 7, 2010Filed: Mar 3, 2016Published: Dec 8, 2016
Est. expiryJul 7, 2030(~4 yrs left)· nominal 20-yr term from priority
A61P 35/00C12Q 1/6886C12Q 2600/158C12Q 2600/118C12Q 2600/156C12Q 2600/178
55
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Biomarkers and methods using the biomarkers for the prediction of the recurrence risk of cancer in a patient are provided.

Claims

exact text as granted — not AI-modified
1 - 26 . (canceled) 
     
     
         27 . A method of treating prostate cancer in a patient comprising:
 (1) obtaining a sample comprising prostate cancer tumor tissue from said patient;   (2) determining the expression of a panel of genes comprising NUSAP1 and UBE2C in said sample comprising prostate cancer tumor tissue;   (3) prognosing the individual as having a decreased likelihood of cancer progression when the expression of the genes NUSAP1 and UBE2C is lower than a threshold index value; and   (4) administering to said patient an effective amount of active surveillance based on the prognosis.   
     
     
         28 . The method of  claim 27 , wherein said determining step further comprises determining the expression of one or more housekeeping genes in said sample. 
     
     
         29 . The method of  claim 28 , wherein said determining step further comprises normalizing the expression of the genes NUSAP1 and UBE2C using the expression of the housekeeping genes. 
     
     
         30 . A method of treating prostate cancer in a patient comprising:
 (1) obtaining a sample comprising prostate cancer tumor tissue from said patient;   (2) determining the expression of a panel of genes comprising NUSAP1 and UBE2C in said sample comprising prostate cancer tumor tissue;   (3) prognosing the individual as having an increased likelihood of cancer progression when the expression of the genes NUSAP1 and UBE2C exceed a threshold index value; and   (4) administering to said patient an effective amount of one or more of chemotherapy, radiation therapy or surgery based on the prognosis.   
     
     
         31 . The method of  claim 30 , wherein said determining step further comprises determining the expression of one or more housekeeping genes in said sample. 
     
     
         32 . The method of claim  43 , wherein said determining step further comprises normalizing the expression of the genes NUSAP1 and UBE2C using the expression of the housekeeping genes.

Join the waitlist — get patent alerts

Track US2016355884A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.